GLP-1 medications are generally intended for long-term use and stopping them is not recommended without first speaking with a doctor
Following the predefined inclusion and exclusion criteria, 36 studies were included in this systematic review and underwent qualitative analysis
It then checks the MHRA list for private eligibility, and the NICE TA1026 four-of-five list for the NHS, with the current rollout cohort applied automatically
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
There was an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis associated with GLP-1RA use compared to usual care
Weekly injections are effective but inconvenient